Shattuck Labs' Quarterly Loss Reaches $25.2 Million As Crohn's Trial Costs Climb

The biotech's research spending rose to $21.6 million from $7.6 million, and it says its cash should last into 2029.

Share
Shattuck Labs' Quarterly Loss Reaches $25.2 Million As Crohn's Trial Costs Climb

Shattuck Labs, which develops antibodies that block a protein called Death Receptor 3 (DR3) to treat inflammatory and immune-mediated diseases, reported a $25.2 million net loss for the third quarter, up from $10.1 million a year earlier. Research spending nearly tripled as the company started a Phase 2b Crohn's disease trial, according to an 8-K filed Thursday.

Trial costs drive the wider loss

Research and development expenses were $21.6 million, against $7.6 million in the third quarter of 2025. General and administrative costs rose to $5.5 million from $4.1 million.

The loss was $0.14 per share in both quarters, because the weighted-average share count grew to about 183.2 million from about 72.2 million. For the first nine months of 2026, the net loss was $55.1 million, compared with $36.2 million in the same period of 2025.

Shares fell 9.71% to $4.65 in Thursday trading, from a prior close of $5.15, on the day the results came out.

Cash into 2029

Cash and short-term investments totaled $196.3 million at September 30, up from $86.1 million a year earlier. The company expects that money to fund operations into 2029, a runway that excludes any new capital, proceeds from business development deals and added clinical costs.

Shattuck, based in Austin, has no approved products. Its lead drug, SL-325, is a DR3-blocking antibody.

Two Phase 2 trials, data in 2028

The Crohn's trial, called RECEPTIVE-CD1, will test three doses of SL-325 against placebo in about 232 patients. Its main goal is endoscopic response at 12 weeks, with data expected in the first half of 2028.

A second Phase 2 trial, in hidradenitis suppurativa, is expected to start in the fourth quarter of 2026. The company submitted its FDA application for it in October and plans about 150 patients, with data also expected in the first half of 2028.

CEO Taylor Schreiber said the two studies should allow direct comparisons with the TL1A antibody class. The company also expects to share initial Phase 1 data in 2027 for SL-846, a DR3 and IL-23 receptor bispecific antibody.

Schreiber presents at Piper Sandler's healthcare conference on December 2-3, after a fireside chat at Evercore ISI's conference on November 30-December 1.

Sources

More on Shattuck Labs

All Shattuck Labs (STTK) coverage →